A b s t r a c t
CD138 (syndecan-1) is a transmembrane heparan sulfate cell surface proteoglycan that mediates a number of cellular functions, including cell-to-cell adhesion, cell-matrix interaction, and cell proliferation and differentiation. 1 The molecule has an important role in the maintenance of cell morphologic features. Within the clinical spectrum of hematologic disorders, expression of syndecan-1, recognized by CD138-clustered antibodies, is highly sensitive and specific for plasmacytic differentiation. In addition, other B cell-lineage hematopoietic neoplasms may also express the molecule, including immunoblastic diffuse large B-cell lymphoma and marginal zone lymphoma. 2 However, its expression is typically limited to the cell population with plasmacytoid morphologic features. 2 In normal nonhematopoietic tissue, CD138 is expressed exclusively by epithelial cells, with the most intense signals found in squamous and transitional epithelia. 3 CD138 immunoreactivity has been observed in epithelial neoplasms of various origins, including those of prostate, colorectum, kidney, and squamous cell origins, [4] [5] [6] [7] although its expression may be lost when normal epithelial cells undergo malignant transformation. 8 CD138 reactivity has also been found in malignant melanomas with epithelioid morphologic features. 2 Syndecan-1 antigen cannot be readily detected in differentiated mesenchymal cells by immunohistochemical analysis, although low levels of the molecule are produced by endothelial cells in cell culture. 3 CD138 reactivity has further been reported in a variety of soft tissue tumors. 2, 9 However, the majority of these tumors exhibited cytoplasmic reactivity, and cell membrane positivity was recognized only in the Upon completion of this activity you will be able to:
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epithelial elements of synovial sarcomas. 2, 9 Expression of CD138 in bone tumors has not been reported in the English language literature. In this study, we aimed to investigate immunoreactivity to anti-CD138 in common bone tumors, namely osteosarcoma, osteoid osteoma, osteoblastoma, chondrosarcoma, and giant cell tumor of bone.
Materials and Methods
After approval by the institutional review board, the surgical pathology database of our institution was searched to identify cases of osteosarcoma, osteoid osteoma, and osteoblastoma. A total of 32 consecutive cases of osteosarcoma were retrieved for a 6-year period (January 2005 to January 2011), of which 5 cases were excluded from further analysis owing to a lack of tumor cells in the subsequent levels. The remaining 27 cases consisted of 13 needle core biopsy specimens and 14 noncore specimens, including incisional biopsy, curettage, and surgical excision specimens. We retrieved 12 cases of benign bone-forming tumors (7 osteoid osteomas and 5 osteoblastomas), including 7 needle core biopsy specimens and 5 noncore specimens. In addition, 17 cases of reactive bone (including fracture callus, reactive new bone formation, and osteomyelitis), consisting of 1 needle core biopsy and 16 noncore specimens, were also included. The patients' demographic information was recorded. In addition, a tissue microarray (TMA) from US Biomax (Rockville, MD), consisting of 60 bone tumors and 9 cases of normal bone (triplicate cores per case, core diameter of 1.0 mm), was also included. Immunohistochemical stains for CD138 were performed in all cases. Tumors were scored as positive and assigned a range of positivity (<5%, 5%-25%, 26%-50%, and >50%) when unequivocal membranous staining was identified regardless of strength. The cases with positive CD138 staining were subsequently stained for immunoglobulin κ and λ (IgK and IgL).
Immunohistochemical studies were performed as previously reported. 10 In brief, 5-μm sections were obtained from formalin-fixed, paraffin-embedded block preparations. Heatinduced epitope retrieval was applied in sodium citrate buffer (0.02 mol/L; pH 6.0) in a heater at 97°C for 20 minutes. The immunostaining was accomplished with a semiautomated immunostainer (Thermo Scientific-Labvision 720, Labvision, Fremont, CA) and an UltraVision LP polymer system (Labvision), using antibodies raised against CD138 (clone MI 15, 1:100 dilution; DAKO, Carpinteria, CA), IgK (clone L1C1, prediluted; Cell Marque, Rocklin, CA), and IgL (clone Lamb14, prediluted; Cell Marque). The chromogen diaminobenzidine tetrachloride was used to visualize the antibodyantigen complex. The tissue was counterstained with hematoxylin. Appropriate positive controls were included. The negative controls were performed by replacing the primary antibodies with normal serum.
Results
A total of 12 benign bone-forming tumors (7 osteoid osteomas and 5 osteoblastomas), from 5 males and 7 females, 6 to 68 years old (mean, 24.5 years), were evaluated. The anatomic sites of tumor were predominantly femur (n = 6), but also included tibia (n = 2), ulna (n = 2), and humerus and sacrum (1 case each) ❚Table 1❚. Ten cases (5 needle core biopsy specimens and 5 noncore specimens) showed at least focal membranous staining of tumoral cells with CD138. Semiquantitative evaluation of these cases revealed 3 cases with less than 5% staining, 1 case showing 5% to 25% reactivity, 5 cases exhibiting 26% to 50% staining, and 1 case displaying more than 50% reactivity ❚Table 2❚ and ❚Table 3❚. There was no significant difference in the percentage of positive staining between the core biopsy and the noncore specimens.
We evaluated 27 in-house osteosarcoma cases from 15 males and 12 females, 10 to 77 years old (mean, 26 years). The anatomic sites of tumor were predominantly femur (n = 9), humerus (n = 5), tibia (n = 4), and pelvis (n = 4) but also included fibula, calcaneus, clavicle, vertebra, and lung (Tables 2 and 3 ). As seen in osteoid osteoma/ osteoblastoma cases, there was no significant difference in the percentage of positive staining between the core biopsy and noncore specimens. All 17 in-house cases of reactive bone, from 7 men and 10 women, 23 to 77 years old (mean, 55.2 years), were nonimmunoreactive with CD138 (Table 2) .
A TMA consisting of 60 bone tumors and 9 cases of normal bone was evaluated. The neoplastic cases included 24 osteosarcomas derived from 15 males and 9 females (14-64 years old; mean, 31 years), 24 chondrosarcomas derived from 13 males and 11 females (12-70 years old; mean, 40 years), and 12 giant cell tumors of bone derived from 5 men and 7 women (28-52 years old; mean, 36.8 years). Two cases of osteosarcoma, both osteoblastic, were positive for CD138 in the range of 5% to 25%. All cases of chondrosarcoma, giant cell tumor of bone, and normal bone were negative for CD138 (Table 2) . Furthermore, normal bone adjacent to osteosarcoma in in-house cases showed nonimmunoreactivity with CD138 (data not shown).
Thus, CD138 expression was seen in 10 (83%) of 12 osteoid osteoma/osteoblastoma cases and in a total of 16 (31%) of 51 osteosarcoma cases, including 14 (52%) of 27 inhouse cases and 2 (8%) of 24 TMA cases, but not in chondrosarcomas, giant cell tumors of bone, or normal/reactive bone. All CD138+ cases were negative for subsequent IgK and IgL staining (data not shown).
Discussion
The role of syndecan-1 in malignancies has been studied in various neoplasms, and variable results were observed in different tumor types and differentiation. 11 In general, expression of the molecule was reduced during the transformation from benign to malignant in epithelial cells, with poorly differentiated tumors showing the greatest loss of syndecan-1. 12, 13 Decreased staining of CD138 has been demonstrated in squamous cell carcinoma of the head and neck, 6,14 colorectal adenocarcinoma, 4 renal cell carcinoma, 5 and hepatocellular carcinoma. 13 In contrast, CD138 has been shown to be overexpressed in prostatic and pancreatic adenocarcinomas. 7, 15 In addition, CD138 immunoreactivity has also been demonstrated in other epithelial neoplasms, including mammary, gastric, pulmonary, and urothelial carcinomas; in medullary and papillary carcinoma of the thyroid; and in thymomas. 2 Rarely, CD138 expression has been reported in some soft tissue tumors, including synovial sarcoma, alveolar soft part sarcoma, malignant epithelioid schwannoma, and fibromatosis. 2, 9 However, the vast majority of CD138 immunoreactivity in these tumors was in the cytoplasm, whereas a membranous staining pattern was seen only in the epithelial elements of synovial sarcoma. Positive CD138 immunostaining was also reported in a case of leiomyosarcoma, although the staining pattern was unclear. 2 To our knowledge, this is the first study to examine CD138 expression in bone tumors. Our results show that approximately 80% of benign bone-forming tumors and one third of osteosarcomas demonstrated CD138 expression in a membranous staining pattern, while all cases of chondrosarcoma, giant cell tumor of bone, and normal/reactive bone were nonreactive or demonstrated a nonspecific cytoplasmic staining pattern. While CD138 expression in bone-forming tumors was rarely diffuse, the staining was typically focal and patchy in the majority of the in-house cases. The fact that only 2 (8%) of 24 cases of osteosarcoma from the TMA displayed CD138 positivity was most likely due to the limited amount of tumor present in the TMA and the inability to evaluate the entire lesional tissue. Thus, CD138 expression in more than 50% in-house osteosarcoma cases likely represents the true rate of CD138+ osteosarcomas. Our data indicate that CD138 expression in bone lesions is not a definitive marker for plasmacytic origin, but also can be seen in benign and malignant bone-forming tumors. While osteoid osteomas and osteoblastomas may be distinguished from plasmacytic neoplasms by their clinical manifestations and radiologic characteristics, the expression of CD138 in osteosarcoma may represent a potential diagnostic pitfall, especially in a bone biopsy specimen in which the nature of the lesion needs to be determined from a limited amount of tissue. Thus, caution is required to interpret CD138+ cells from a bony lesion for which a hematologic etiology has not been established, especially when not all neoplastic cells are immunoreactive with CD138. In addition, when plasma cell neoplasm is in the differential diagnosis, IgK and IgL, along with other appropriate markers and radiologic correlations, are needed to reach the correct diagnosis.
